Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to assess efficacy and safety in combination of resminostat and sorafenib in Asian patients with advanced HCC previously untreated with systemic chemotherapy.
Epistemonikos ID: 1678815186d0015bb1316a35a4308d9504c189e7
First added on: May 12, 2024